Hailshadow
Atossa Therapeutics (ATOS) is up ~11% in Thursday trading after reporting that the US FDA has granted Rare Pediatric Disease designation to Duchenne Muscular Dystrophy candidate “Z”-Endoxifen.
If “Z”-Endoxifen is eventually approved, Atossa would be eligible for a Priority Review voucher that could be sold to another company.
“Z”-Endoxifen is a selective estrogen receptor modulator that Atossa says has 100 times greater potency than existing SERMs with better tolerability. It is also under investigation for breast cancer.
